1.The Preventive Effect of Brazilian Propolis on Metabolic
Ken YASUKAWA ; Yurika TSUDA ; Tetsuya HARIGAYA ; Yasuhito NOBUSHI ; Shigetoshi TSUTSUMI ; Keiichi MATSUZAKI ; Yukinaga KISHIKAWA
Japanese Journal of Complementary and Alternative Medicine 2017;14(2):77-82
Objective: To show the preventive effect of Brazilian propolis on metabolic syndrome.Methods: Nine Brazilian propolis were examined for inhibition ofα-glucosidase, absorption of sugar in mice, and lipid accumulation, glycerol 3-phosphate dehydrogenase, and adiponection production in mouse 3T3-L1 cells.Results: In nine Brazilian propolis, AF-06, AF-19, and AFG-06 propolis inhibited rat internal α-glucosidase, and AF-06 propolis inhibited the absorption of sugar in mice. In 3T3-L1 cells, AF-06 and AF-08 propolis inhibited accumulation lipid, and inhibited glycerol 3-phosphate dehydrogenase.Conclusion: Brazilian propolis AF-06 and AF-08 are natural products which offer promise in the prevention of diabetes and metabolic syndrome. Incorporating dietary supplements into a treatment plan with medicines with similar effects requires further study.
2.Statistic Analysis About the Actual Situation of Crude Drug Prescription Based on the Survey Conducted by the Board of Crude Drug Materials of JSOM
Kyoko TAKAHASHI ; Hiroki UEDA ; Tetsuya HARIGAYA ; Kayoko SHIMADA-TAKAURA ; Takahiro YAMADA ; Denichiro YAMAOKA
Kampo Medicine 2019;70(4):399-408
The treatment by Kampo decoction is partly covered by National Health Insurance in Japan. However, this system is facing bankruptcy crisis because of rising prices of crude drugs in China, their main producer. The board of crude drug materials of the Japan Society for Oriental Medicine (JSOM) distributed questionnaires to 7416 JSOM member doctors, and performed statistical analysis (with JSOM approval) of 1877 answers to visualize the data. Twenty-six percent of respondents said that they had prescribed a decoction, and 29% of respondents said they had not, but wanted to prescribe a crude drug. Eighty-eight percent of doctors who prescribe decoctions offered medical treatment primarily to insured patients. Nine percent offered medical treatment at patients' own expense. The latter group prescribed decoctions more frequently. Many doctors were aware of the financial risk of prescribing crude drugs imposed by the drug price standard and rising crude drug import prices. Four hundred and fifty-five doctors explained when they were most inclined to prescribe a decoction. Thirty-five percent of these said they used decoctions when they couldn't treat patients with extracts. This result implies a necessity for decoctions. Many doctors said they prescribed decoctions for autoimmune or allergic diseases. Financial constraints were the most frequently cited barrier to treatment with decoctions. This survey made clear the financial difficulties clinics are facing. We therefore calculated the amount of crude drugs used for decoctions to validate the possibility of their domestic production.